Dawn of Heart Muscle Patches to Address Lost Myocardium in Heart Failure
The Phase 1-2 trial enrolled 20 patients and found the patches integrated with damaged myocardium while improving heart function and quality of life.
4 Articles
4 Articles
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in
GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon, a biotechnology company developing regenerative cardiac therapies, today announced that clinical results evaluating its engineered human heart muscle tissue for patients with advanced heart failure have been published in the New England Journal of Medicine (NEJM). The publication concludes that restoration of heart muscle function in patients with advanced heart …
The Record
Financial PostGroundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon, a biotechnology company developing regenerative cardiac therapies, today announced that clinical results evaluating its engineered human heart muscle tissue for patients with advanced heart failure have been published…
Dawn of Heart Muscle Patches to Address Lost Myocardium in Heart Failure
(MedPage Today) -- For people with advanced heart failure, modular tissue-engineered patches showed promise as a way to remuscularize the heart, according to interim data. Biologic ventricular assist tissue (BioVAT) was epicardially transplanted...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
